PRAME 300–309 (HLA-A*02:01)
( ALYVDSLFFL )

ALYVDSLFFL is a linear peptidic epitope (epitope ID225231) studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human), tested in T cell assays. Antigen Peptide PRAME 300–309 (HLA-A*02:01) ALYVDSLFFL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Sequence:	ALYVDSLFFL
Gene:	PRAME
Delivery:	1-3 days
C-Terminus:	OH
N-Terminus:	H
Amount:	1 mg
Counter Ion:	TFA
Protein:	Melanoma antigen preferentially expressed in tumors
Species:	Human
Allele:	HLA-A*02:01
Application :	Flow Cytometry
Indication :	Cancer
Purity :	95% HPLC-MS

Protocols and Tips

Handling peptides

Data sheets

Safety data sheet poly peptides:

Do you have any questions concerning this product?

Special references for this product will come soon.
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >

€105.00*

Prices excl. VAT plus shipping costs

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS

Amount in mg

1 mg

5 mg

Product number: EP11397_1

More PRAME peptides

PRAME 100-108 (HLA-A*02:01) ( VLDGLDVLL )

The PRAME 100-108 peptide with the amino acid sequence VLDGLDVLL is a linear epitope (epitope ID 869501) derived from the Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395). It is used to stimulate human Prame (100-108)-specific CD8+T cells. PRAME belongs to the cancer/testis antigens in Homo sapiens. This antigen is notably overexpressed in various solid tumors, including melanoma, epithelial ovarian cancer, multiple sarcoma subtypes, and non-small cell lung cancer, while its expression in healthy tissues is mostly restricted to the testes. The PRAME 100-108 (VLDGLDVLL) epitope is presented by the MHC class I HLA-A*02:01 allele and was initially identified by Kessler et al. in 2001. In their studies, they demonstrated that cytotoxic T lymphocytes, which recognize this high-affinity binding epitope, could specifically target and lyse melanoma, lung, mammary, renal cell and cervical cancer cell lines.

From €105.00*

Details

PRAME 242-251 (HLA-A*3) ( CTWKLPTLAK )

From €105.00*

Details

PRAME 254-262 (HLA-A24), human ( PYLGQMINL )

From €105.00*

Details

PRAME 300–309 (HLA-A*02:01) ( ALYVDSLFFL )

From €105.00*

Details

PRAME 301-309 (HLA-A*24) ( LYVDSLFFL )

From €105.00*

Details

PRAME 425-433 (HLA-A*02:01) ( SLLQHLIGL )

PRAME 425-433 (SLLQHLIGL) is a linear peptidic epitope (epitope ID 459114) studied as part of Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395), a cancer/testis antigen from Homo sapiens. PRAME is highly expressed in several solid tumors such as melanoma, epithelial ovarian cancer, multiple sarcoma subtypes and non-small cell lung cancer, while in healthy tissue it is almost exclusively restricted to the testicles. Therefore, it is a promising target for adoptive T cell therapies. PRAME 425-433 (SLLQHLIGL) was first described by Kessler et al. in 2001. In their experiments, cytotoxic T lymphocytes recognizing the high affinity binding, HLA-A*0201–restricted PRAME epitope specifically lysed melanoma, renal cell, lung, mammary, and cervical carcinoma cell lines.

From €105.00*

Details

PRAME/OIP4 Peptide Pool, human

Pool of 125 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (UniProt ID: P78395) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€285.00*

Request a Quotation

Your Contact Information

Quotation Sent!

PRAME 300–309 (HLA-A*02:01)
( ALYVDSLFFL )